Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis

• Principais autores: Delphine Staumont‐Sallé (Autor), Sébastien Barbarot (Autor), Jean David Bouaziz (Autor), Chan Chan (Autor), Claire Clibborn (Autor), Aurélie Du‐Thanh (Autor), Claire Feeney (Autor), Alexandre Lejeune (Autor), Laurent Misery (Autor), Audrey Nosbaum (Autor), Julien Seneschal (Autor), Angèle Soria (Autor), Fan Zhang (Autor)
• Formato: Livro
• Publicado em: Wiley, 2023-09-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Background Eosinophilia is common in patients with atopic dermatitis (AD). Abrocitinib, an oral Janus kinase‐1 inhibitor and dupilumab, an anti-interleukin‐4 receptor‐α antibody, are approved for moderate‐to‐severe AD. Dupilumab has been associated with transient eosinophilia. Objectives To...